Arcellx Investor Relations Material
Latest events
Status Update
Arcellx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arcellx Inc
Access all reports
Arcellx, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of cancer and other severe diseases. The company's approach centers around engineering immunotherapies, particularly those based on CAR-T cell technology, to target specific cancers. Arcellx is headquartered in Redwood City, California, and its shares are listed on NASDAQ.
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
ACLX
Country
🇺🇸 United States